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ABSTRACT
Radford, Shari M. M.S., Purdue University, December 2016. Structure-Function
Analysis of the Dopamine Transporter in the Presence of Synthetic Cathinones and
Amphetamines. Major Professor: Eric L. Barker.
The dopamine transporter (DAT) is a monoamine transporter that regulates
dopamine (DA) neurotransmission by clearing DA from the synapse. DAT is acted
on by a number of psychostimulant drugs, which block reuptake and potentiate DA
signaling. Several inhibitors of DAT, both amphetamines and cathinones, also cause
reversal of transport. Previous research has shown the importance of a conserved
salt bridge in another monoamine transporter, the serotonin transporter, in
amphetamine-induced eﬄux. In our studies here, we engineered a mutant
Drosophila melanogaster DAT (dDAT D475N) designed to interrupt this salt bridge
and examine the eﬀects on amphetamine- and cathinone-induced eﬄux in vitro.
Understanding the mechanism of action of structurally similar yet functionally
diverse psychostimulants necessitates information about their binding sites at the
transporter. A second mutant D. melanogaster DAT (dDAT D121G) was
engineered to more closely mimic the substrate binding site of human DAT. By
using already existing crystal structure data, compounds were computationally
docked to the identiﬁed binding sites, allowing prediction of binding poses and
binding free energies. dDAT D475N was found to have similar inhibition of uptake
by synthetic cathinones relative to wild-type. No signiﬁcant drug-induced eﬄux was
observed in dDAT wild-type or dDAT D475N, while the D121G mutant restored
eﬄux activity beyond that of human DAT. These results show that the presence of
a salt bridge at the external gate of DAT, as well as a hydrophobic environment
within the DA binding site, are important for drug-induced eﬄux.

1

1. PSYCHOSTIMULANT DRUGS AND THE DOPAMINE
TRANSPORTER
1.1

The Synapse

Nerve cells communicate with one another through chemical signaling and the
release of neurotransmitters across the space between cells, known as the synapse.
Classical neurotransmitters include acetylcholine, the amino acids glutamate,
γ-aminobutyric acid (GABA), and glycine, and the monoamines dopamine (DA),
norepinephrine (NE), and serotonin (5-HT) [1]. Monoamines are synthesized from
the amino acids tyrosine or tryptophan through a series of enzymatic reactions.
Monoamines are then packaged into vesicles by vesicular monoamine transporters
(VMATs) [2]. An action potential causes depolarization of the neuronal membrane
at the axon terminal, triggering fusion of vesicles to the presynaptic membrane [3].
Monoamines are then released into the synapse, where they bind to postsynaptic
receptors and pass on a signal. Neurotransmission is halted by removing
neurotransmitter from the synapse. Neurotransmitters may be degraded by
enzymes, taken up by nearby glial cells, or recycled into the presynaptic cell by
transporter proteins. The monoamine transporters- dopamine transporter (DAT),
norepinephrine transporter (NET), and serotonin transporter (SERT)- are
responsible for reuptake of DA, NE, and 5-HT, respectively, from the synapse
(Figure 1.1) [4]. VMATS have a higher substrate turnover rate than monoamine
transporters, keeping the cytosol free of neurotransmitters and repacking
monoamines into vesicles for later release. Monoamine oxidase (MAO) and
catechol-O-methyl transferase (COMT) act within the cell to break down free
catecholamine neurotransmitters.
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Psychostimulant drugs inﬂuence mood by increasing synaptic neurotransmitter
levels, potentiating signal and stimulating neurons in reward pathways of the brain.
Cocaine and amphetamines produce their psychoactive and addictive eﬀects
primarily by inhibiting monoamine transporters, increasing synaptic levels of DA,
NE, and 5-HT [5, 6]. An initial buildup of dopamine in the mesolimbic system gives
rise to euphoria and a desire to take the drug again. Blockade of DAT is necessary
for cocaine and amphetamine reward, demonstrated by mutagenesis and DAT
knockout studies in mice. Mice lacking a functional dopamine transporter show no
conditioned place preference, locomotor activity, or DA release upon exposure to
cocaine or amphetamine, indicating that the dopamine transporter is a target of
psychostimulants [7, 8]. The short time course of DA release in the nucleus
accumbens plays a role in reward and behavior [9]. The nucleus accumbens receives
information from the amygdala, prefrontal cortex, and hippocampus that is then
converted to behavior through connections with the extrapyramidal motor
system [10]. Long-term psychostimulant use leads to an accumulation of the
transcription factor ΔFosB in the limbic system and long-term changes in neural
structure, which has been correlated with addiction-like behaviors in mice [11, 12].
While psychostimulant use has acute eﬀects on synaptic neurotransmitter levels,
chronic use can lead to permanent changes in the brain.

1.2

Psychostimulant Drugs

According to the the United Nations World Drug Report 2016, 247 million
people used illicit drugs within the past year, and 29 million of those people were
addicted [13]. The United States 2014 National Survey on Drug Use and Health
found that 27 million, or 10.2%, of Americans had used an illicit drug within the
past year [14]. Commonly abused drugs include cannabis, alcohol, heroin, cocaine,
and methamphetamine. The drugs are generally categorized as either stimulants or
depressants. Here, I will discuss the mechanism of action of some classical and
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Figure 1.1.: Schematic interaction of DAT and amphetamine in the synapse.
Vesicles release DA from the presynaptic cell, which crosses the synapse to interact
with DA receptors. DAT terminates signaling by clearing DA from the synapse. In
the presence of amphetamines, DA transport is inhibited through competition for
uptake with drug. Amphetamines also induce eﬄux, a reversal of the DAT transport cycle.
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Figure 1.2.: Structure of monoamine neurotransmitters, amphetamine, cathinone,
and novel psychoactive substances.
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relatively new psychostimulants, including amphetamine, cathinone, and derivative
structures which act on monoamine transporters (Figure 1.2). A more complete
understanding of psychostimulant activity in the brain could lead to novel
pharmacological interventions for the treatment of substance addiction.

1.2.1

Cocaine

Cocaine, a β-alkaloid found in the Erythroxylon coca plant, has been used by
humans since at least 600 AD in Peru [15, 16]. Cocaine was ﬁrst isolated from coca
leaves by Albert Neimann in 1855, and was the ﬁrst recorded anesthetic [17]. Local
administration of cocaine blocks voltage-gated sodium channels in nerve cells,
preventing depolarization and blocking conduction of electrical impulses, leading to
the anesthetic eﬀect [1, 18]. Cocaine also acts on monoamine transporters to block
reuptake of DA, NE, and 5-HT when administered systemically, leading to a
euphoric feeling. Noting its ability to elevate mood and increase alertness,
companies began selling cocaine in a multitude of products. In the 1880s, cocaine
could be found in cigarettes, wine, and solutions sold with hypodermic needles.
Coca Cola’s original recipe containing cocaine was marketed as a temperance drink
without the vices of alcohol. In 1879, cocaine was recommended for the treatment
of morphine addiction [15, 16]. Cocaine itself is a highly addictive and reinforcing
drug, used in a multitude of animal models, and is one of the best studied drugs of
addiction. Chronic repeated use leads to tolerance through a variety of mechanisms
including increased density of alpha and beta adrenergic receptors in the brain and
depletion of DA stores, resulting in drug cravings, lethargy, and anhedonia after
cessation of use [19]. The addictive properties of cocaine were eventually realized
and the 1914 Harrison Narcotics Act limited sale outside of prescription use. The
1970 Controlled Substances Act further restricted cocaine in the United States,
placing it on Schedule II as a drug with accepted medical use but high abuse
potential [20]. From 1970-1987, the high cost of cocaine hindered widespread use,
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but lowered 1982-1984 black market pricing led to an increase in abuse. A 1988
study found that cocaine available on the street was only an average of 40% pure,
adulterated with substances like sugar and caﬀeine [21]. Fluctuations in price and
purity led to varying use statistics of the drug; 2014 cocaine use was estimated to
be 1.5 million people, or 0.6% of the United States population, with 1.4% of those
aged 18-24 having used cocaine within the past month [14].

1.2.2

Amphetamines

Amphetamine use can lead to feelings of euphoria similar to cocaine, and also has
high potential for dependence. The structure of amphetamine is quite unique from
cocaine, characterized by an α-methyl-phenethyl-amine motif (Figure 1.2). The ﬁrst
synthetic amphetamine was made by Lazar Edeleanu at the University of Berlin in
1887 [22]. Amphetamine became commercially available without a prescription in
1936 as Benzedrine 10 mg tablets, sold by Smith Kline and French. The drug
enhances attention and alertness, helping to ameliorate symptoms in patients with
narcolepsy and attention deﬁcit hyperactivity disorder (ADHD). Amphetamines
have also been used historically in warfare, notably in boosting wakefulness in
ﬁghter pilots during World War II [23]. Widespread recreational use of the drug
began after release of a publication from the University of Minnesota, where the
Psychology Department did a study on alertness [24]. In 2014, 0.6% of Americans
had used illegal stimulants within the past month, 0.2% of which were
methamphetamine users [14]. Amphetamine use also has a number of detrimental
side eﬀects, including psychosis and restlessness. In fact, rodents chronically
administered amphetamine are used as a model of schizophrenia [25]. Due to this
and other dangerous eﬀects, amphetamine and methamphetamine were placed on
the United States Drug Enforcement Agency (DEA) Schedule II list of controlled
substances in 1971 [20].
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Amphetamine’s eﬀect comes from a combination of factors in the central nervous
system. The primary sites of action are at the monoamine transporters DAT, NET,
and SERT [26]. Amphetamines have dual action at these transporters, causing both
blockade and reversal of transport. Amphetamine drugs are most selective for DAT
and NET, with lower potency at SERT [27]. Amphetamines also inhibit vesicular
monoamine transporter 2 (VMAT2) [28]. Finally, amphetamines inhibit MAO, an
enzyme that breaks down monoamines like DA,NE, and 5-HT. The combined
eﬀects of amphetamines lead to an increase in neurotransmitter levels at the
synapse. Figure 1.1 demonstrates the eﬀects of amphetamine at DAT. The Barker
lab is interested in studying the eﬀects of amphetamines and cathinones at the
dopamine transporter, speciﬁcally the molecular mechanism of transport reversal,
or eﬄux.

Ecstasy (MDMA)
Ecstasy, or 3,4-methylenedioxymethamphetamine (MDMA) is the classic party
drug [?, 29]. Incidence of use is only a fraction of cocaine, where 0.2% of Americans
over the age of 12 had used MDMA in the last month, with higher use (0.8%) in
those age 18-25 [14]. MDMA, ﬁrst synthesized at Merck Pharmaceuticals in 1912, is
a ring substituted amphetamine that is also closely related to the hallucinogen
mescaline [30]. Ecstasy is typically ingested orally in capsules or tablets.
Much is known about the mechanism of MDMA action, yet much remains to be
studied. MDMA acts primarily at monoamine transporters, with similar potency at
SERT, NET, and DAT [31]. Highly eﬃcacious 5-HT release by MDMA at SERT
potentiates serotonergic signaling, leading to its hallucinogenic and empathogenic
eﬀects [29, 31, 32]. MDMA also inhibits tryptophan hydroxylase, the rate-limiting
enzyme in the synthesis of serotonin [33]. The combination of serotonin depletion
and deﬁciency in 5-HT synthesis after MDMA use may lead to negative side eﬀects
such as irritability for days after ingestion. MDMA is metabolized primarily in the
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liver by CYP2D6, with glucoronide and sulfate metabolites excreted in the
urine [32]. Chronic use of MDMA may lead to permanent damage to serotonergic
nerve terminals [34, 35]. A single dose of MDMA leads to reduced 5-HT levels one
week following use, and chronic use leads to a constitutive reduction in 5-HT as
well as increased 5-HT1A receptors in the postsynaptic cell in rats [36]. Chronic use
has also been modeled in mice, where 4 days of repeated administration followed by
2 weeks of abstinence has been found to cause a reduction in SERT expression and
5-HT levels, with no eﬀect on NE, NET, DA, or DAT levels [37]. Abstinent human
users also have a reduction in serotonin markers [38].
MDMA use can lead to feelings of well-being, euphoria, and closeness to others,
but also has risks of anxiety, elevated heart rate, sweating, and other unpleasant
side eﬀects. Alexander Shulgin coined the term empathogen to describe the
experience of emotional connectedness that occurs due to MDMA use. Due to its
empathogenic properties, MDMA was used as a psychotherapeutic tool in the 1970s
and early 1980s [39, 40]. The DEA added MDMA to Schedule I in 1985 due to
apparent risk of addiction [20]. There was a resurgence of use in the 1990s club
scene, quickly curbed by a public health campaign until a later resurgence in 2009.
There is evidence of a low risk of dependence to MDMA, which may be in part due
to the cultural use of drug in speciﬁc social settings [41]. MDMA is currently in
Phase II clinical trials for use in the treatment of post-traumatic stress disorder
(PTSD) and has been approved for Phase III clinical trials [42, 43]. More research
about MDMA and related compounds is crucial at a time when the drug may soon
be available to millions of Americans by prescription.

Synthetic Cathinones
Closely related to amphetamines by structure are the cathinones, which contain a
beta keto group (Figure 1.2). Within the past ten years, synthetic cathinones have
emerged on the market and are being used recreationally. Many are currently
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available as legal highs, skirting drug laws due to their unique structures; they may
be labeled as “plant food,” “bath salts,” or “not for human consumption.” Due to
the relative novelty of these compounds, much remains to be studied about their
cellular targets as well as long-term eﬀects. Cathinones are thought to have similar
targets and eﬀects to the structurally similar amphetamines. In 2010, the three
most common cathinone drugs were methylone, mephedrone, and
3,4-methylenedioxypyrovalerone (MDPV) [27]. These three synthetic cathinones
were banned by the United Kingdom in 2010, closely followed by a Schedule I
classiﬁcation by the DEA in 2011 [20].

Methylone (MDMC)
Methylone, or methylenedioxymethcathinone (MDMC) is the beta-keto analogue
of MDMA (Figure 1.2); users experience similar energetic and empathogenic
feelings [44]. Like other synthetic cathinones, methylone is a white powder that is
taken orally in capsules or tablets, dissolved in water, or snorted [45]. Some users
also report injecting, although this method is uncommon. MDMC, like MDMA, has
similar selectivity for each of the monoamine transporters DAT, NET, and
SERT [27]. Rats administered MDMA or MDMC have hyperactivity and
comparably elevated 5-HT levels in the nucleus accumbens. Interestingly, rats
administered MDMC had brain levels of DA, NE, and 5-HT similar to those of
untreated rats after 2 weeks of chronic administration, while MDMA-treated rats
had decreased 5-HT levels. Both rats and mice treated with a 4-day binge of
MCMC showed no signs of depression, anxiety, or memory problems 2 weeks after
cessation of treatment [46]. Treatment had no eﬀect on neurotransmitter levels or
number of monoamine transporters 2 weeks post-binge treatment. This contrasts to
amphetamine treatment, which has been shown to cause widespread DA depletion
in rodents [47, 48].
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Expanding the methylenedioxy ring of MDMA and MDMC to an ethylenedioxy
ring makes ethylenedioxymethamphetamine (EDMA) and ethylenedioxy
methcathinone (EDMC) (Figure 1.2) [44]. These compounds have lower potency at
NET and DAT than MDMA or MDMC, but are more tolerated by SERT due to its
larger and more ﬂexible binding site [49, 50].

Mephedrone (4-MMC)
Mephedrone, also known as 4-methylmethcathinone (4-MMC), ﬁrst became
available on the internet in 2007 [51]. 4-MMC acts similarly to MDMA and
cocaine, which had declining purity and increasing costs at the time. The ease of
purchasing mephedrone, legality, purity, and low price led to a rapid rise in its
popularity. In 2010, the largest incidence of 4-MMC use was found to be in those
age 16-24, 4.4%, which was equal to that of cocaine use [52]. 4-MMC targets DAT,
NET, and SERT with approximately equal selectivity, enhances DA release, and is
about twice as potent as MDMC [27, 53]. 4-MMC is metabolized by reduction of
the keto group, N-demethylation, and oxidation of the tolyl moiety [45]. Much like
MDMC, rats administered 4-MMC had brain levels of DA, NE, and 5-HT similar to
those of untreated rats after 2 weeks of chronic administration. Like MDMC, both
rats and mice treated with a 4-day binge of 4-MMC showed no signs of depression
or anxiety 2 weeks later [46]. Treatment had no eﬀect on neurotransmitter levels or
number of monoamine transporters 2 weeks post-treatment. However, mice showed
reduced memory performance in the T-maze. Similarly, high-dose administration
led to memory deﬁcits in rats [45] In another study, high-dose administration of
4-MMC enhanced spatio-temporal learning in primates. Thus, the long-term eﬀects
of 4-MMC are complex and worthy of further study.
One reason 4-MMC may not have a long-term eﬀect on neurotransmitter levels
or depression is because amphetamine and MDMA have micromolar aﬃnity for
VMAT2 while the aﬃnity of cathinones cannot be determined. Methamphetamine
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and MDMA cause VMAT2 release of DA while the cathinones have <35% DA
releasing eﬀect at an EC50 of >100 μM in in vitro studies [54]. Another
contributing factor could be due to amphetamines, but not their beta-keto
analogues, binding to trace amine-associated receptor 1 (TAAR1), a G-protein
coupled receptor that regulates presynaptic dopaminergic neurotransmission,
reuptake inhibition, and neurotransmitter eﬄux [55–57].

MDPV
Methylenedioxypyrovalerone (MDPV), another one of the ﬁrst synthetic
cathinones, was placed on the DEA Schedule I along with MDMC and 4-MMC in
2011. A closely related analogue with a pyrovalerone ring,
α-pyrrolidinopentiophenone (α-PVP), was scheduled in 2013. MDPV and α-PVP
are highly potent and selective blockers at DAT [45, 58]. The bulky pyrrolidine ring
makes MDPV an inhibitor, but not substrate, of DAT as compared to the synthetic
cathinones discussed above. Selectivity for DAT is thought to be in large part due
to the length of the α-carbon side chain in both structures. The R(-) enantiomer is
signiﬁcantly more potent, although MDPV is supplied as a racemic mixture [59].
MDPV is metabolized by CYP2D6, CYP2C19, and COMT, undergoing
glucuronidation before renal excretion [45]. Similar to cocaine, it has been shown to
be reinforcing and self-administered by rodents, as well as identiﬁed in drug
discrimination tests.
The immediate eﬀects of amphetamines and cathinones are due to their action at
monoamine transporters. Blockade of transporters leads to accumulation of
neurotransmitter and propagated signaling. Long-term potentiation of signaling can
lead to permanent changes in neural structures. Better understanding of how
psychostimulant drugs act at their primary target is needed to advance the ﬁeld
and aid in treatment or prevention of drug abuse and addiction.
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1.3

Transporter Structure

DAT, NET, and SERT belong to the SLC6 family of neurotransmitter:sodium
symporter (NSS) membrane proteins, controlling signaling by clearing
neurotransmitters from the synapse and regulating neurotransmitter levels.
Dysregulation of neurotransmitters plays a large role in depression, anxiety, and
addiction. We can learn more about structure-function relationship between drugs
and monoamine transporters by comparing the pharmacological eﬀect a drug has to
its mechanism of action and binding site(s).
Monoamine transporters are proteins composed of 12 transmembrane alpha
helices. They can be found in neurons near the synapse, ready to reuptake
dopamine, serotonin, or norepinephrine and return neurotransmitter to the
pre-synaptic cell. Neurotransmitter:sodium symporters function according to the
alternating access model, switching between an outward open conformation where
they pick up substrate from the extracellular milieu, to an inward open
conformation where the substrate binding site is exposed to the cytoplasm (Figure
1.3) [60–62]. The passage of substrate is coupled to the movement of sodium down
its concentration gradient. Data from a bacterial NSS homolog, A. aeolicus leucine
transporter (LeuT), provides information about intermediate transition states. Due
to their familial relationship, LeuT and DAT have high structural similarity despite
low sequence identity. High resolution structural information (up to 1.9 Å) is
available for LeuT in the two conformations proposed by the alternating access
model as well as an intermediate state, where substrate is occluded from both sides
of the membrane [63, 64].
Without substrate, the transporter is free to sample all conformations from
inward open to outward open [65]. Binding of sodium stabilizes an outward facing
conformation, facilitating substrate binding [66, 67]. After substrate binds,
transporter transitions to an occluded state. Small localized conformational changes
in residues near the dopamine binding site, called gating residues, control access to
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Figure 1.3.: Alternating access model for DAT.
Outward Open: Dopamine (DA) and sodium (Na+ ) enter the transporter from the
extracellular space. Occluded: Transporter shifts to hold DA occluded from access
to either side of membrane. Inward Open: Transporter opens to intracellular space,
allowing DA transport. DAT then returns to outward open, ready to transport another DA molecule.
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each side of the cellular membrane. The extracellular gate closes and then release of
an intracellular gate is associated with protein transition from occluded to inward
open [65, 68]. The extracellular gate in dDAT is composed of R52 and D475.
Monoamine transporters have two proposed substrate binding sites [66, 69, 70].
The central (S1) site is where endogenous neurotransmitter, selective serotonin
reuptake inhibitors, cocaine, and amphetamines bind (Figure 1.4) [63, 71, 72]. The
allosteric S2 site is about 12 Åtoward the extracellular side of the central binding
site (Figure 1.5). Tricyclic antidepressants have been shown to bind at the S2 site
LeuT and SERT [72–75]. Computational studies on DAT suggest that binding of
DA at the S2 site promotes translocation of DA from the S1 site [76]. There are
also a few allosteric modulator quinazolinamine compounds with currently
unknown binding sites [77].

1.3.1

Experimental Structure

Crystallography on the leucine transporter provided an initial look at the
structure of neurotransmitter:sodium symporters [63]. Penmatsa et al. published
the ﬁrst crystal structure of the Drosophila melanogaster dopamine transporter
(dDAT) in 2013 [71]. Since then, the Gouaux lab has investigated binding of
antidepressants and cocaine analogues, leading to several high resolution crystal
structures of dDAT in the outward-open state and one structure in an occluded
state [78, 79]. The Gouaux lab has also revealed a crystal structure for the human
serotonin transporter (hSERT) [72].

1.3.2

Computational Structure

Molecular modeling and protein-ligand docking software can be used to predict
the position of small molecules noncovalently bound to macromolecular protein
targets. Docking is especially important when predicting binding poses of drugs
with known activity in order to establish the structural basis of a drug‘s binding
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Figure 1.4.: Model of the S1 binding site in dDAT.
The S1 binding site consists of amino acids F43, D46, A117, V120, D121, Y124,
F319, F325, S421, and S422 interacting with dopamine. Adapted from [78], PDB
code 4Xp1.
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Figure 1.5.: Model of the S2 binding site in dDAT.
The S2 binding site consists of amino acids R52, Y123, I127, W130, F216, I220,
L221, D312, Q316, P386, F471, and D475 forming an allosteric pocket. The
extracellular gate is composed of a salt bridge between R52 and D475. Adapted
from [78], PDB code 4Xp1.
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aﬃnity. Docking is also a key computational method used in structure-based drug
design for the screening of small molecule libraries in lead identiﬁcation. One of the
most widely used and user-friendly docking programs available is AutoDock
Vina [80, 81].

1.3.3

Eﬄux and the External Gate

Forward translocation of substrate from the extracellular milieu to the cytoplasm
by monoamine transporters has been well studied. Drugs such as cocaine bind to
the substrate binding pocket of the transporter and stabilize the protein in an
extracellular-facing conformation [82, 83]. Amphetamines and certain cathinones
can induce a reversal of the transport cycle and cause eﬄux of neurotransmitter out
of the cell. There are still unanswered questions about the mechanism of
transporter-mediated substrate eﬄux.
The N-terminus of DAT has been implicated in amphetamine-induced eﬄux.
Although truncation of the ﬁrst 22 amino acids of hDAT does not change the
transporter‘s ability to uptake DA, it leads to an 80% reduction in
amphetamine-induced eﬄux in experiments measuring [3 H] labeled DA levels [84].
Measuring amperometric current in voltage clamped cells with truncated hDAT
leads to a 91% reduction in amphetamine-induced eﬄux. The N-terminus contains
several serines available for phosphorylation. Mutations of the ﬁrst ﬁve serine
residues in hDAT to alanine prevents phosphorylation; mutation does not eﬀect DA
uptake but reduces voltage measured by amperometric experiments. Conversely,
mutation to the ﬁrst ﬁve serines in hDAT to aspartate retains its ability to both
uptake and eﬄux. Interactions with syntaxin1A, protein kinase C (PKC) and
calcium/calmodulin-dependent protein kinase II (α-CaMKII) enhance
amphetamine-induced eﬄux [26, 85]. N-terminal phosphorylation of the dopamine
transporter is crucial to drug-induced eﬄux.
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In the serotonin transporter, a mutation near the substrate recognition site
allows binding, but not transport of amphetamines [86]. A charged pair of residues
(D/E to R) at the extracellular gate is conserved across nearly all monoamine
transporters (Figure 1.6(a)). This putative salt bridge is thought to prevent leak of
5-HT out of the cell by stabilizing the protein and reducing conformational
ﬂexibility in the inward open conformation. Drosophila SERT (dSERT) has an
uncharged asparagine at the extracellular gate and is unable to eﬄux in the
presence of amphetamines. The hSERT E493N mutant destabilizes the extracellular
gate and is also unable to eﬄux. After aligning the sequences of SERT and DAT,
the analogous mutation was found in dDAT and is predicted to have equivalent
eﬀects. I hypothesized that the D475N mutation would abolish
amphetamine-induced eﬄux found in wild-type (WT) dDAT. This novel gating
mutant may give structural insight into the function of transporters, as well as
amphetamine action on transport proteins.
High sequence identity (52.4%) and similarity (69.2%) between hDAT and dDAT
make the Drosophila melanogaster protein a useful tool in studying human DAT.
Sequence similarity corresponds to structural similarities in DA recognition, uptake,
and eﬄux. However, diﬀerences in the potency of amphetamines and other
substrates between human and drosophila DAT have been observed [87], potentially
due to a change in two residues near the S1 binding site (D121 and S426).
Formation of a D121G mutant mimicking the residue found at this position in
hDAT may restore dDAT functional selectivity to that of hDAT (Figure 1.6(b)).
The aim of this dissertation is to create a more comprehensive understanding of
DAT and monoamine transporter eﬄux function by addressing structurally similar
yet functionally diverse drug binding and pharmacological eﬀects. The central
hypothesis of this work is that the extracellular salt bridge in DAT is important to
drug-mediated eﬄux. This was assessed by testing the eﬀect of two separate
mutations (D121G and D475N) on the pharmacology of drug-induced eﬄux at
dDAT. I determined the binding poses and free energies of two binding sites for
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(a) A highly conserved acidic residue across SLC6 family
transporters forms part of the extracellular gate.

(b) The S1 binding site of human and drosophila DAT is
highly conserved.

Figure 1.6.: Sequence alignments of select monoamine transporters.
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various ligands using AutoDock Vina. By making mutations to DAT that change
its sensitivity to amphetamine-induced eﬄux, we can better understand how the
transporter functions and what exactly amphetamine is acting upon in the
wild-type transporter to elicit its eﬀect. Understanding how psychostimulants
interact with DAT, where they bind, and how they block natural substrate passage,
will tell more about drug and transporter mechanisms of action.
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2. AMPHETAMINE AND CATHINONE
PHARMACOLOGY AT DAT
2.1
2.1.1

Materials and Methods
Materials

HEK293 GripTite MSR cells stably expressing hDAT were generously provided
by Keith Henry (University of North Dakota). [3 H]DA (30 Ci/mmol) and
[3 H]MPP+ (80 Ci/mmol) were purchased from PerkinElmer. dDAT D121G
mutagenesis was performed by GenScript. Mazindol, cocaine, methamphetamine,
MDMC, 4-MMC, MDPV, and unlabeled MPP+ were obtained from SigmaAldrich.
MDMA was a gift from Dr. David Nichols (Purdue University).

2.1.2

dDAT D475N Construction

Wild-type dDAT DNA was obtained from Addgene. pBluescriptSKII vector and
oocyte transcription vector containing dDAT were digested with KpnI and NotI;
the resulting fragments were gel-puriﬁed, and complementary fragments were
ligated to yield dDAT in a bacterial expression vector. Construction of a mutant
insert was completed by GenScript, introducing the D475N mutation and a silent
mutation to BamHI between BglII and Tth111I restriction sites in pUC57.
Mutation was conﬁrmed by restriction enzyme digestion. The mutant sequence was
cloned into pBluescriptSKII.
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2.1.3

Cell Culture

HEK293 cells stably expressing the dDAT WT and dDAT D475N genes were
produced. cDNAs in pBluescriptSKII were digested with KpnI/NotI and subcloned
into pcDNA3.1+ . Wild type HEK293 cells were transfected with each gene using
lipid-mediated transfer (Lipofectamine 2000; Invitrogen) as described by the
manufacturer. Transfected cells were selected with 400 μg/mL genetecin (G418;
Invitrogen). Selected colonies were characterized for [3 H]DA uptake.
HEK293 cells stably expressing dDAT WT or dDAT D475N were maintained in
Dulbecco’s modiﬁed Eagle’s medium with 5% dialyzed fetal bovine serum and 5%
Fetal Clone I supplemented with penicillin, streptomycin, L-glutamine, and G418
(400 μg/mL). Cells were grown in a 37°C humidiﬁed environment with 5% CO2 .
HEK293 GripTite MSR cells stably expressing hDAT were maintained in
Dulbecco’s modiﬁed Eagle’s medium with 5% dialyzed fetal bovine serum and 5%
Fetal Clone I supplemented with penicillin, streptomycin, L-glutamine, Geneticin
(600 μg/mL) and G418 (400 μg/mL). Cells were grown in a 37°C humidiﬁed
environment with 5% CO2 .

2.1.4

[3 H]DA Uptake Inhibition Assays

HEK293 cells stably transfected with dDAT WT, HEK293 cells stably
transfected with dDAT D475N, or HEK293 cells transiently transfected with dDAT
D121G using Lipofectamine 2000 (Invitrogen) were plated in 24-well plates
precoated with poly-D-lysine (1*105 cells/well). The next day, cells were washed
with KRH (120 mM NaCl, 4.7 mM KCl, 1.2 mM KH2 PO4 , 1.2 mM MgSO4 , 10 mM
HEPES, 2.2 mM CaCl2 , pH 7.4) and then bathed in KRH with 5 mM glucose.
Drugs (cocaine, methamphetamine, MDMC, 4-MMC, and MDPV) were added at
increasing concentrations (1 nM-100 μM) and allowed to incubate for 10 minutes at
37°C. Three wells were left untreated to account for total uptake, while 10 μM
mazindol was used to determine nonspeciﬁc uptake in an additional 3 wells. All
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wells were treated in triplicate. 40 nM [3 H]DA with the antioxidant L-ascorbic acid
(10 μM) and MAO inhibitor pargyline (10 μM) was added and incubated for an
additional 10 minutes. Cells were washed twice with KRH and solubilized in
MicroScint-20. The following day plates were read on a PerkinElmer TopCount
NXT scintillation counter to measure [3 H] accumulation.

2.1.5

[3 H]DA Uptake Kinetics Assays

HEK GripTite 293 MSR cells stably transfected with hDAT, HEK293 cells stably
transfected with dDAT WT, or HEK293 cells stably transfected with dDAT D475N
were plated in 24-well plates precoated with poly-D-lysine (1*105 cells/well). The
next day, cells were washed with KRH (120 mM NaCl, 4.7 mM KCl, 1.2 mM
KH2 PO4 , 1.2 mM MgSO4 , 10 mM HEPES, 2.2 mM CaCl2 , pH 7.4) and then
bathed in KRH with 5 mM glucose, 10 μM pargyline, and 10 μM ascorbic acid.
Decreasing concentrations of [3 H]DA were added and allowed to incubate for 10
minutes at 37°C. 10 μM mazindol was used to determine nonspeciﬁc uptake. Cells
were washed twice with KRH and solubilized in MicroScint-20. Plates were read on
a PerkinElmer TopCount NXT scintillation counter to measure [3 H] accumulation
the next day.

2.1.6

[3 H]DA Eﬄux Rate Assays

HEK GripTite 293 MSR cells stably transfected with hDAT or HEK293 cells
stably transfected with dDAT WT were plated in 24-well plates (1*105 cells/well).
The next day, cells were washed with KRH (120 mM NaCl, 4.7 mM KCl, 1.2 mM
KH2 PO4 , 1.2 mM MgSO4 , 10 mM HEPES, 2.2 mM CaCl2 , pH 7.4) and bathed in
KRH with 5 mM glucose. All work was completed in duplicate wells. Cells were
preloaded with 40 nM [3 H]DA for 20 minutes at 37 °C, with four wells pretreated
with 10 μM mazindol. Twelve wells were treated with 100 μM methamphetamine
and twelve wells were treated with KRH. Eﬄux was terminated at 0, 1, 2, 3, and 5
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minutes by washing twice in KRH. Cells were solubilized in MicroScint-20 and [3 H]
was quantiﬁed on a PerkinElmer TopCount NXT scintillation counter.

2.1.7

[3 H]MPP+ Eﬄux Assays

HEK GripTite 293 MSR cells stably transfected with hDAT, HEK293 cells stably
transfected with dDAT WT, HEK293 cells stably transfected with dDAT D475N,
or HEK293 cells transiently transfected with dDAT D121G using Lipofectamine
2000 (Invitrogen) were plated in 24-well plates (1*105 cells/well). The next day,
cells were washed with KRH (120 mM NaCl, 4.7 mM KCl, 1.2 mM KH2 PO4 , 1.2
mM MgSO4 , 10 mM HEPES, 2.2 mM CaCl2 , pH 7.4) and bathed in KRH with 5
mM glucose. All work was completed in quadruplicate wells. The ﬁrst four wells
were treated with 10 μM mazindol and all cells were preloaded with 340 μM
[3 H]-MPP+ for 20 minutes at 37 ○ C. The ﬁrst eight wells were terminated to
account for nonspeciﬁc and total uptake. Remaining wells were treated with KRH
or a single concentration of drug (10 μM methamphetamine, 10 μM MDMA, 10 μM
MDPV, 1 μM MDMC, 10 nM 4-MMC). Eﬄux was allowed for 10 minutes at 37 °C,
then terminated by washing twice in KRH. Cells were solubilized in MicroScint-20
and [3 H] was quantiﬁed on a PerkinElmer TopCount NXT scintillation counter.
Drug-induced eﬄux was calculated by subtracting nonspeciﬁc uptake and
normalizing to MPP+ remaining to the amount of [3 H] remaining after 10 minutes
of basal eﬄux.

2.1.8

Data Analysis

IC50 values for drug-inhibited uptake were estimated using nonlinear curve-ﬁtting
analysis (GraphPad Prism 6 software, San Diego, CA). All results were expressed
as mean ± standard error of the mean (SEM) for at least three experiments
performed in triplicate unless otherwise noted.
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Multiple t-tests were completed to compare basal and drug-induced eﬄux.
*p≤0.05, **p≤0.01, ***p≤0.001.

2.1.9

Protein-Ligand Docking

AutoDock Vina software was used to calculate binding free energy and poses of
drugs on the 4Xp9 crystal structure of dDAT using methods outlined by Forli et
al. [88]. Drugs docked were D-amphetamine, dopamine, methamphetamine,
methylone (MDMC), mephedrone (4-MMC), MDPV, and MDMA. Receptor side
chains at the S1 site (F43, D46, A117, V120, D121, Y124, F319, F325, S421, and
S422) were treated as ﬂexible during docking. Docking was also performed using a
structure mutated to contain G121. Docking poses were inspected visually to
ensure results were consistent with the binding pose of D-amphetamine shown in
the 4Xp9 crystal structure. Search space was 16x16x16 Åalong the binding site
identiﬁed in the crystal structure.
Docking at the S2 binding site was performed with the same drugs, treating side
chains at the S2 site (R52, Y123, I127, W130, F216, I220, L221, D312, Q316, P386,
F471, and D475) as ﬂexible. Docking was also performed using a structure
containing N475. Docking poses were inspected visually to ensure ligand was
docked within the binding site. Search space was 18x18x26 Åalong the binding site
identiﬁed in the LeuT crystal structure.

2.2
2.2.1

Results
Uptake Inhibition Results

The Barker lab previously engineered a series of SERT mutants demonstrating
the importance of a charge in the outer gate to MDMA-induced eﬄux [86]. A
highly conserved structure, the salt bridge has been shown to be essential to
drug-induced eﬄux. The extracellular gate of dDAT was shown in Figure 1.5. A
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(a) Mazindol inhibition of DA Uptake

Figure 2.1.: Mazindol inhibition of DA Uptake
Mazindol inhibition of DA uptake in HEK-293 cells stably transfected with wild
type and D475N DAT or transiently transfected with dDAT D121G. [3 H]DA uptake
assays were performed as described in Materials and Methods. Data were plotted
as percentage of total DA uptake. Results shown represent mean ± standard errors
of triplicate determination and are representative of at least three independent
experiments.
Summary of IC50 values (95% conﬁdence interval): ○WT IC50 = 35 nM (20-61 nM),
◻D475N IC50 = 18 nM (4.9-66 nM), ◇D121G IC50 = 5.1 nM (3.1-8.4 nM).
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(a) Meth inhibition of DA Uptake

(b) MDPV inhibition of DA Uptake

(c) 4-MMC inhibition of DA Uptake

(d) MDMC inhibition of DA Uptake

Figure 2.2.: Psychostimulant inhibition of DA Uptake
Drug inhibition of DA uptake in HEK-293 cells stably transfected with wild type
and D475N DAT. [3 H]DA uptake assays were performed as described in Materials
and Methods. Nonspeciﬁc uptake was determined with 10 μM mazindol. Data were
plotted as a percentage of speciﬁc DA uptake. Results shown represent mean ±
standard errors of triplicate determination and are representative of at least three
independent experiments.
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dDAT mutant (D475N) was designed to test if presence of a charged residue at the
extracellular gate was also important to eﬄux function in DAT. To investigate the
role of D121 in uptake and eﬄux, a D121G mutant was made to mimic the residue
found at this position in hDAT. Uptake inhibition experiments were ﬁrst performed
with the stimulant drug mazindol to ensure that cells were expressing dDAT and
able to uptake DA (2.1(a)). Mazindol was an especially potent inhibitor of the
D121G mutant, with an IC50 of 5 nM, nearly ten times less than that of wild-type
DAT.
Uptake inhibition experiments by psychostimulant drugs showed only slight
diﬀerences in uptake between dDAT WT and dDAT D475N (Figure 2.2). Table 2.1
summarizes the IC50 values established by uptake inhibition experiments. These
ﬁndings revealed that amphetamines and synthetic cathinones remain capable of
binding dDAT with either aspartic acid or asparagine at the outer gate.
Uptake kinetics experiments revealed diﬀerences between hDAT, dDAT, dDAT
D475N. hDAT had lowest maximal velocity (Vmax ) and Km (the substrate
concentration at which the reaction rate is half of Vmax ) for uptake. The dDAT
D475N mutant slowed DA uptake rate compared to wild-type dDAT, not reaching
Vmax within the DA concentrations tested.
Table 2.1: Summary of DA uptake inhibition IC50 Values
Mazindol

MDPV

Meth

MDMC

4-MMC

WT

-7.5±0.1

-4.3±0.2

-5.4±0.1

-4.3±0.7

-4.0±0.2

D475N

-7.7±0.3

-4.8±0.3

-6.5±0.5

-4.0±0.1

-4.2±0.2

Estimated IC50 values (log M) for inhibition of [3 H]DA uptake in stably transfected
HEK-293 cells. IC50 values represent mean ± standard errors for at least three independent experiments.
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2.2.2

Eﬄux Results

I attempted to assess drug-induced eﬄux of DA. Although eﬄux occurred, there
was no diﬀerence between the amount with and without amphetamine drugs.
Hypothesizing that there is a high amount of basal eﬄux, I tested the rate of eﬄux
with 100 μM methamphetamine treated and vehicle treated cells (Figure 2.3). Due
to the high rate of basal eﬄux, there was no apparent drug-induced eﬄux in human
or drosophila DAT. Dopamine is a highly reactive molecule that is subject to
oxidation, which could lead to a decrease in signal over time. It is also somewhat
polar, making the ligand able to diﬀuse through plasma membranes.
1-methyl-4-phenylpyridinium (MPP+ ) is a positively charged substrate of DAT
which will not oxidize or cross the membrane as easily. Leaky cells allowed an
excess of MPP+ to cross back through the membrane, but not to the same
magnitude as DA (Figure 2.4). While dDAT D475N had overall lower raw counts
per minute of tritium, both dDAT mutants exhibited similar levels of basal eﬄux
compared to WT.
Drug-induced reversal of MPP+ transport was tested in hDAT, dDAT, dDAT
D475N, and dDAT D121G. Both methamphetamine and MDMA induced a change
over basal eﬄux in hDAT and dDAT D121G (p≤0.05) (Figure 2.5). The cathinone
4-MMC induced eﬄux in hDAT but not dDAT or any dDAT mutants at the 10 nM
concentration. MDPV and MDMC did not induce eﬄux in any of the experiments.
While methamphetamine and 4-MMC may have induced some eﬄux in dDAT WT,
drug-induced eﬄux did not reach statistically signiﬁcant levels, which is likely due
to high basal eﬄux relative to total uptake. Cells expressing dDAT D475N had no
notable drug-induced eﬄux.

2.2.3

Docking Results

Docking simulations using AutoDock Vina were completed to investigate drug
binding at the S1 and S2 sites and see if a diﬀerence in binding modes could
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(a) dDAT eﬄux rate

(b) hDAT eﬄux rate

Figure 2.3.: Basal and drug-induced eﬄux rate of DA from DAT
Eﬀects of 100 μM methamphetamine or vehicle on the eﬄux of [3 H]DA in cells
stably expressing dDAT or hDAT. Cells were loaded with [3 H]DA (40 μM) for 20
minutes and eﬄux induced as described in Materials and Methods. There is no
diﬀerence in eﬄux rate between methamphetamine and untreated cells.
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Figure 2.4.: Basal DA and MPP+ Eﬄux
Total uptake and basal eﬄux of [3 H]MPP+ and [3 H]DA in cells stably expressing
dDAT. Cells were loaded with [3 H] substrate for 20 minutes and immediately
terminated or allowed to incubate for an additional 10 minutes as described in
Materials and Methods. Basal eﬄux of DA was greater than basal eﬄux of MPP+ .
Results shown represent mean ± SEM and are representative of ﬁve independent
experiments.
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(a) 10 μM Meth-induced MPP+ Eﬄux

(b) 10μM MDPV-induced MPP+ Eﬄux

(c) 10 nM 4-MMC-induced MPP+ Eﬄux

(d) 1 μM MDMC-induced MPP+ Eﬄux

(e) 10 μM MDMA-induced MPP+ Eﬄux

Figure 2.5.: Drug-induced MPP+ Eﬄux
(Continued on the following page.)

33

Figure 2.5.: Eﬀects of drug on the eﬄux of [3 H]MPP+ in cells expressing hDAT,
dDAT, dDAT D475N, or dDAT D121G. Cells were loaded with [3 H]MPP+ (340
μM) for 20 minutes and eﬄux induced by drug as described in Materials and Methods. Drug-induced eﬄux occurred in hDAT and dDAT D121G. * p≤0.05, ** p≤0.01,
*** p≤0.001. Results shown represent mean ± SEM of quadruplicate determination
and are representative of three independent experiments. Basal eﬄux was calculated as the amount of [3 H] remaining after 10 minutes without drug treatment.
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account for the diﬀerence in uptake and eﬄux between WT and the dDAT
mutants. To investigate the role of D121 at the S1 site, docking was performed on
WT and a D121G mutant. This mutation is expected to enhance human-like
receptor recognition at the site and increase apparent drug potency, represented by
higher drug aﬃnity. Calculations demonstrated similar poses (Figure 2.6, 2.7) and
scores (Table 2.2) between the site variants. The aromatic ring of 4-MMC shifts
positions from perpendicular to Y124 in dDAT WT to nearly parallel to Y124 in
the dDAT D121G mutant. MDMC was actually 0.6 kcal/mol more aﬃne to the
dDAT WT S1 binding site than dDAT D121G, suggesting that the binding pose is
a more accurate ﬁt for drosophila than human DAT.
In order to verify predictive accuracy at the S1 site, the calculated docking pose
of D-amphetamine and D-amphetamine density in the amphetamine bound LeuT
crystal structure (PDB ID 4XP9) were compared. All-atom RMSD between the
computational and experimental ligand was calculated to be 1.087 Å. Accuracy at
the S2 site is more diﬃcult to determine because there is no crystal interaction with
which to compare. The approved pose was chosen as the highest aﬃnity dock
within the proposed binding site that had at least one similar calculated pose.
Consistent with previous ﬁndings, the S1 site has much higher aﬃnity for
dopamine and psychostimulant drugs than the S2 site. In the case of all drugs
studied here, drugs had higher aﬃnity for the binding sites than endogenous
dopamine (Table 2.2). This is supportive of their role as potent competitive
inhibitors, out-competing DA for its binding site. Docking poses at WT and D475N
S2 binding site are shown in Figures 2.8 and 2.9. There were only small diﬀerences
between calculated aﬃnities for drug binding at the S2 site between WT and
D475N protein. Low aﬃnity scores suggest that conﬁdence in the docking poses at
the S2 binding site was low. dDAT crystal structures have not yet been solved in
the inward open conformation, where the extracellular vestibule is closed. Residues
surrounding the S2 site in the amphetamine bound LeuT crystal structure (PDB
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ID 4XP9) may have been too far apart to accurately predict ligand binding when
protein is in this conformation.

(a) Dopamine

(b) Meth

(c) MDMC

(d) 4-MMC

(e) MDPV

(f) MDMA

Figure 2.6.: Model of drugs docked to the S1 binding site of wild-type dDAT
All ligands adopt a similar pose with the positively charged side chain pointing
toward D46 and the ring moiety pointing into the binding pocket toward V120 and
D121.
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(a) Dopamine

(b) Meth

(c) MDMC

(d) 4-MMC

(e) MDPV

(f) MDMA

Figure 2.7.: Model of drugs docked to the S1 binding site of dDAT D121G
Ligands adopt a similar pose with the positively charged side chain pointing toward
D46 and the ring moiety pointing into the binding pocket toward V120. The tolyl
ring of 4-MMC is rotated further into the binding pocket compared to the other
ligands.
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(a) Dopamine

(b) Meth

(c) MDMC

(d) 4-MMC

(e) MDPV

(f) MDMA

Figure 2.8.: Model of drugs docked to the S2 binding site of wild-type dDAT
Ligands interact with the extracellular gate R52 and D475. MDPV is unique
because the pyrovalerone ring interacts with R52, while other ligands interact along
their carbon side-chains.
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(a) Dopamine

(b) Methamphetamine

(c) MDMC

(d) 4-MMC

(e) MDPV

(f) MDMA

Figure 2.9.: Model of drugs docked to the S2 binding site of dDAT D475N
Ligands interact with R52 but are docked further outside the proposed binding site,
interrupting the extracellular gate when compared to the wild-type protein.
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Table 2.2: Computationally determined binding aﬃnities (kcal/mol) for ligands at
dDAT S1 and S2 binding sites
WT S1

D121G S1

WT S2

D475N S2

Dopamine

-6.1

-6.2

-4.4

-4.5

MDPV

-9.0

-9.4

-6.6

-6.0

Meth

-6.3

-6.2

-4.8

-4.8

MDMC

-7.9

-7.3

-5.4

-5.2

4-MMC

-7.1

-7.1

-5.4

-5.5

MDMA

-7.7

-7.5

-5.1

-5.1

Binding aﬃnities (kcal/mol) calculated in AutoDock Vina. Ligands were docked to
the S1 binding site of wild-type and humanized D121G dDAT structure. Ligands
were also docked to a model of the S2 binding site with both wild-type dDAT and
D475N gating mutant.
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3. DISCUSSION
3.1

Discussion of Results

Amphetamines and synthetic cathinones have limited medical use and a high
potential for dependence and abuse. Addictive properties are caused largely by
their action on DAT and the monoamine transporters leading to increased
concentrations of DA in the synapse and activation of brain reward pathways [6].
Diﬀerent regions of DAT have been implicated for substrate recognition and
transport. The substrate binding (S1) site was identiﬁed in a crystal structure of
dDAT (PDB ID 4XP1), and computational studies on DAT, as well as crystal
structures of the homologous LeuT (PDB ID 2Q6H) and hSERT (PDB ID 5I6X)
proteins suggest an allosteric S2 site. Although many studies have explored the
inward and outward transport of substrate in DAT and other SLC6 transporters,
the molecular mechanisms of transporter eﬄux is not fully understood. A point
mutation in hSERT (D493N) abolishes MDMA-induced eﬄux [86]. Here the
analogous mutant dDAT D475N was used to further explore the role of the
extracellular gate in amphetamine-induced eﬄux. Three relatively new cathinone
analogue drugs were utilized to investigate the interaction of structurally similar yet
functionally diverse drugs on DAT.
Cells expressing dDAT, dDAT D121G, and dDAT D475N, were all able to
translocate DA and MPP+ . DA uptake was inhibited by drugs at similar potencies,
demonstrating that the D475N gating mutant does not interfere with DA uptake.
Amara and colleagues showed that dDAT is less selective for cocaine and
amphetamines than hDAT [87]. Consistent with this trend, methylone,
mephedrone, and MDPV were had IC50 values at least tenfold less potent at dDAT
than hDAT [53].
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Both dDAT and hDAT exhibit basal eﬄux of DA and MPP+ . Previous
experiments in the Barker lab demonstrate that dSERT also exhibits basal eﬄux of
5-HT, while hSERT does not [86]. This was hypothesized to be due to the absence
of the salt-bridge. The data shown herein suggest that basal eﬄux is also due to
additional residues not present in hSERT. Basal eﬄux of [3 H]DA may be due to
DA degradation, but [3 H]MPP+ is not as susceptible to oxidation. Diﬀerences in
transfection eﬃciency between the two genes could also contribute to discrepancies.
The amount of cell surface expression was not determined and could contribute to
diﬀerences in measured eﬄux.
hDAT and dDAT D121G exhibited drug-induced eﬄux with methamphetamine
and MDMA, while dDAT WT and dDAT D475N did not. Consistent with its
action as a cocaine-like inhibitor, MDPV did not induce eﬄux in any of the
experiments. Interestingly, MDMC prevented basal eﬄux through the leaky hDAT
and dDAT WT transporters. Experiments in hDAT showed no statistically
signiﬁcant release of neurotransmitter by MDMC even at >100 μM
concentrations [53]. Docking experiments showed that MDMC had high aﬃnity for
the S1 site, second only to MDPV. It is possible that MDMC spends more time at
the S1 site and prevents transporter reversal on the timescale tested. My results
suggest that the D121 residue in the S1 site of dDAT and perhaps further
unidentiﬁed residues make dDAT less sensitive to eﬄux than hDAT. BLAST
sequence alignment between hDAT and dDAT show very low sequence similarity at
the N-terminus [89]. N-terminus phosphorylation has been demonstrated to be
critical in amphetamine-induced eﬄux [84, 90]. The shortened dDAT N-terminus
could also contribute to the lack of measurable eﬄux in dDAT.
Models can be used to make predictions about ligand binding to transporter
proteins like DAT in computational docking studies, and should be cross-validated
with biological studies [91, 92]. Binding modes predicted by ligand docking display
insights into the aﬃnity and selectivity of ligands for dDAT. While algorithms are
good at scoring binding poses, they should not be used to compare the relative
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aﬃnity of a series of ligands. The empirical scoring algorithm employed by
AutoDock Vina does not fully account for factors such as hydrophobic contribution,
explicit electrostatic interactions, and hydrogen bonding, making the software
inaccurate at estimating binding free energy [80]. Scores are, however, useful for
assessing conﬁdence in the pose, where a reduction in calculated aﬃnity after
mutation could mean the pose is more questionable in the mutant.
In this dissertation, I report models of amphetamine and several cathinone
analogues bound to dDAT. Transporter conformation used in docking should be
physically realistic and represent functional states relevant to binding. Residues
around the binding sites were treated as ﬂexible to provide a small amount of
conformational diversity and allow the docking algorithm to yield accurate binding
poses. I hypothesized that ligands bind to dDAT in an open-to-out conformation in
the S1 site for both wild-type and D121G transporter. I hypothesized that the
binding pose of ligands to the D475N mutant would diﬀer from wild-type, with
lower binding aﬃnity. Figures 2.7 and 2.8 include poses for ligands for both WT
and D121G S1 sites using AutoDock Vina, while Figures 2.9 and 2.10 show poses
for ligands at the S2 site for WT and D475N. The poses and calculated binding
aﬃnities were nearly identical at the S1 site, while ligand binding was shifted more
through the extracellular gate in the D475N mutant at the S2 site. Similar poses at
both the WT and mutant S1 site suggest D121 may be involved in the
conformational changes necessary for drug-induced eﬄux. The crystal structure of
D-amphetamine in complex with dDAT provides experimental validation of the
pose for amphetamine in this model [78].
Together, these data contribute to a better model for substrate-induced eﬄux of
the monoamine transporters. Future research on the dopamine transporter will be
useful in treating addiction and toxicity resulting from the use of amphetamine and
its analogues.
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3.2

Future Directions

Previous studies have demonstrated a channel mode of operation for monoamine
transporters [93–95]. Electrophysiolocial studies with two-electrode voltage clamp
in oocytes expressing DAT could be used to assess whether drugs induce an inward
current comparable to that observed for DA and are thus acting as substrates.
hDAT and dDAT may diﬀer in transport turnover rate for inward transport versus
outward transport/eﬄux. The D475-R52 extracellular gate charge interaction may
inﬂuence the reorientation of substrate containing dDAT back to outward open.
Additionally, residues around the S1 site may interact with other transmembrane
domains to stabilize a speciﬁc conformation that is favorable for outward transport.
Structural biology experiments can look directly at the static structure of DAT;
crystallography has been used to capture the protein in various drug-bound states.
Another possible method of studying structure is using cryogenic electron
microscopy (cryo-EM) to bypass some of the challenges associated with X-ray
crystallography. Double electron-electron resonance (DEER) or ﬂuorescence
resonance energy transfer (FRET) look at dynamics of protein movement. Cysteine
crosslinking MTS assays could be used to assess pore accessibility changes by the
D475N mutant, and a shift from open to occluded conformations.
Structural studies require pure protein to carry out experiments. I have
expressed and puriﬁed dDAT WT and dDAT D475N protein that may be used in
future experiments. First attempts at overexpression were done in bacteria based
on the expression of LeuT used for its crystal structure. Although bacterial
expression proved unsuccessful, I was able to express DAT in High5 insect cells.
This diﬀers from the expression of dDATmfc in human embryonic kidney (HEK)
cells, used in the ﬁrst DAT crystal structure [71].
Although X-ray crystallography provides valuable information about the
structure of proteins, it is unable to reveal much about the dynamics of protein
movement. DAT is believed to adopt three diﬀerent conformations with a possible
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fourth channel-like state, but the transition between each state is still a topic of
study. Molecular dynamics (MD) simulations allow further understanding of how
these transitions occur. Molecular dynamics simulations using a model of DAT
based on LeuT could be used to predict the transition between conformations, and
identify other residues that are important in reversal of transport. By performing
MD simulations on models of dDAT docked with psychostimulants, we can observe
and predict how the drugs act to inhibit conformational change and better
understand drug mechanisms. The structure of LeuT has been used as a template
for computational modeling of SERT, and similar techniques can be used to model
the structural dynamics of DAT [86]. Docking could be veriﬁed in other programs
or used to explore other amphetamine and cathinone derivatives. Docking results
should also be validated through structural biology experiments such as
crystallography or cryo-EM.
The results presented in this dissertation show that the presence of a salt bridge
at the external gate of DAT, as well as a hydrophobic environment within the DA
binding site, are important for drug-induced DA eﬄux. Better understanding of the
molecular mechanisms underlying drug-induced substrate eﬄux could lead to better
treatments for drug addiction.
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